3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Primary Myelofibrosis
23
Myeloproliferative Disorders
15
Leukemia, Myeloid, Acute
14
Polycythemia Vera
10
Leukemia
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Myelodysplastic Syndromes
9
Graft vs Host Disease
8
Thrombocythemia, Essential
7
Recurrence
6
Neoplasms
6
Lymphoma, T-Cell
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Myelodysplastic-Myeloproliferative Diseases
3
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Prolymphocytic, T-Cell
3
Leukemia, Myelomonocytic, Chronic
3
Hematologic Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Bronchiolitis Obliterans Syndrome
3
Triple Negative Breast Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Interventions
pembrolizumab
105
Specimen Handling
55
Magnetic Resonance Spectroscopy
48
Biopsy
47
Nivolumab
40
Paclitaxel
35
Gemcitabine
30
Radiosurgery
29
Carboplatin
28
Irinotecan
22
Ipilimumab
22
Cyclophosphamide
22
Cisplatin
22
trastuzumab deruxtecan
21
Leucovorin
19
Capecitabine
19
Fluorouracil
18
Cetuximab
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
18
Pemetrexed
17
Fulvestrant
17
Drug Therapy
16
Docetaxel
16
Taxes
15
Oxaliplatin
15
olaparib
14
abemaciclib
14
Radiotherapy
14
palbociclib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
ruxolitinib
×
1 year
×
Clear all
NCT06397313
2025-09-23
POTAMI-61
Ryvu Therapeutics SA
Phase 2
Recruiting
230 enrolled